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Although blood lead levels in the United
States and other industrialized nations have
declined over the past decades, pockets of
high lead exposure and widespread low-level
lead exposures still persist (Pirkle et al. 1994).
Moreover, a substantial proportion of the
population has had higher lead exposure from
leaded gasoline and other sources such as sol-
dered cans, paints, and tap water in the past
(Pirkle et al. 1994). The long-term conse-
quences of lead exposure include circulatory
diseases, kidney diseases, and neurologic dis-
orders (Cheng et al. 2001; Harlan 1988;
Hertz-Picciotto and Croft 1993; Hu et al.
1996a; Kopp et al. 1988; Lin et al. 2003;
Martin et al. 2006; Moller and Kristensen
1992; Nash et al. 2003; Pirkle et al. 1985;
Schwartz 1991, 1995; Tsaih et al. 2004).
Lead exposure has been associated with
increased blood pressure and hypertension in
cross-sectional as well as longitudinal studies
(Cheng et al. 2001; Harlan 1988; Hertz-
Picciotto and Croft 1993; Hu et al. 1996a;
Kopp et al. 1988; Martin et al. 2006; Moller
and Kristensen 1992; Nash et al. 2003; Pirkle
et al. 1985; Schwartz 1991, 1995). More
recently, there is evidence of increased mor-
tality from circulatory causes in individuals
with blood lead levels of 20–29 μg/dL in the
past (Lustberg and Silbergeld 2002).
However, the association between lead levels
and risk for future ischemic heart disease
(IHD) after controlling for potential con-
founders has not been established. The three
previous reports on the possible association
between lead levels and cardiovascular disease
found no such evidence (Kromhout 1988;
Moller and Kristensen 1992; Pocock et al.
1988). These reports used blood lead level as
a biomarker for lead exposure, which is now
known to poorly reﬂect the cumulative inter-
nal dose of lead. Instead, more recently, bone
lead has become the biologic marker of
choice to assess long-term lead exposure
(Landrigan 1991). With the development of
in vivo K X-ray fluorescence (KXRF), it is
now possible to safely and rapidly measure
bone lead in large-scale epidemiologic studies
(Landrigan and Todd 1994).
The objective of our study was to assess
the relationship of bone and blood lead levels
with risk for IHD (fatal and nonfatal) in a
longitudinal cohort of aging men.
Materials and Methods
Study population. Participants in our study
were from the Normative Aging Study
(NAS), a longitudinal study of aging estab-
lished by the Veterans Administration (now
Department of Veterans Affairs) in 1961 (Bell
et al. 1972). The study cohort initially con-
sisted of 2,280 community-dwelling men who
were health-screened from the Greater Boston
area; those with chronic medical conditions
such as heart disease, diabetes, cancer, peptic
ulcer, gout, recurrent asthma, bronchitis, or
sinusitis were excluded. Those with either sys-
tolic blood pressure > 140 mm Hg or diastolic
blood pressure > 90 mm Hg were also
excluded. The men were between 21 and 80
years of age (mean, 42 years) on entry into the
cohort. Participants subsequently returned for
examinations every 3–5 years during the fol-
low-up period. At each visit, extensive physical
examination, laboratory, anthropometric, and
questionnaire data were collected. 
Measurement of blood lead began in
1988 during each continuing regularly sched-
uled visit of the participant. Beginning in
September 1991, permission was sought from
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BACKGROUND: Lead exposure has been associated with higher blood pressure, hypertension, elec-
trocardiogram abnormalities, and increased mortality from circulatory causes. 
OBJECTIVE: We assessed the association between bone lead—a more accurate biomarker of chronic
lead exposure than blood lead—and risk for future ischemic heart disease (IHD).
METHODS: In a prospective cohort study (VA Normative Aging Study), 837 men who underwent
blood or bone lead measurements at baseline were followed-up for an ischemic heart disease event
between 1 September 1991 and 31 December 2001. IHD was defined as either a diagnosis of
myocardial infarction or angina pectoris that was confirmed by a cardiologist. Events of fatal
myocardial infarction were assessed from death certiﬁcates. 
RESULTS: An IHD event occurred in 83 cases (70 nonfatal and 13 fatal). The mean blood, tibia,
and patella lead levels were higher in IHD cases than in noncases. In multivariate Cox-proportional
hazards models, one standard deviation increase in blood lead level was associated with a 1.27 (95%
conﬁdence interval, 1.01–1.59) fold greater risk for ischemic heart disease. Similarly, a one standard
deviation increase in patella and tibia lead levels was associated with greater risk for IHD (hazard
ratio for patella lead = 1.29; 95% conﬁdence interval, 1.02–1.62). 
CONCLUSIONS: Men with increased blood and bone lead levels were at increased risk for future IHD.
Although the pathogenesis of IHD is multifactorial, lead exposure may be one of the risk factors. 
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measurements. Consenting individuals
reported to the Ambulatory Clinical Research
Center of the Brigham and Women’s Hospital
in Boston. Of the 1,278 participants seen for
their regularly scheduled NAS visits from
1 September 1991 through 31 December
2001, our study included participants who
had information on either blood or bone lead
level and had at least one follow-up visit in
this time frame (n = 1,019). The major reason
given for nonparticipation in the bone lead
study was the inconvenience involved in mak-
ing a separate visit to our bone lead test facil-
ity. After excluding participants with a history
of IHD (myocardial infarction or angina)
before their year of baseline lead measurement
visit, the final data set for analysis included
837 participants. These 837 participants had
their baseline lead measurement done during
their first scheduled visit after September
1991. Approval for this study was obtained
from the Human Research Committees of
Brigham and Women’s Hospital and the
Department of Veterans Affairs Outpatient
Clinic. This study complied with all applicable
requirements of the United States (including
institutional review board approval), and all
participants gave written informed consent
before the study.
History and physical parameters. Each
NAS participant reported to the study center
in the morning after an overnight fast and
abstinence from smoking. At the start of the
visit, height and weight were measured with
the participant wearing only stockings and
undershorts. A complete medical history,
including identity and purpose of medica-
tions taken daily, was elicited by a physician.
A history of physician-diagnosed diabetes
mellitus and hypertension since the last visit
was also elicited. A participant was considered
as having a family history of hypertension if
either a parent or a sibling had hypertension.
The American Thoracic Society questionnaire
(Ferris 1978) was used to assess current smok-
ing and past history of smoking, and the
Food Frequency Questionnaire (Ward et al.
1994; Willett et al. 1988) was used to assess
alcohol consumption. 
The participants were asked about history
of heart disease since their last visit. Every
report of IHD event was reviewed by a board-
certiﬁed cardiologist, who was unaware of the
participant’s blood and bone lead levels. The
criteria for myocardial infarction and angina
pectoris were those used in the Framingham
Heart Study (Shurtleff 1974). A diagnosis
of myocardial infarction was defined by
unequivocal electrocardiographic changes
(i.e., pathologic Q waves), diagnostic
increases in serum glutamic-oxaloacetic
transaminase and lactic dehydrogenase, and
concurrent chest discomfort consistent with
myocardial infarction, or by autopsy. Angina
pectoris was diagnosed when the participant
reported recurrent chest discomfort that
lasted up to 15 min and was distinctly related
to exertion and relieved by rest or nitroglyc-
erin. Events of fatal IHD were assessed from
death certificates. Regular mailings to NAS
participants were used to maintain vital status
information, and death certificates were
obtained for all decedents. 
Immediately after the history was obtained,
blood pressure was measured using a standard
mercury sphygmomanometer with a 14-cm
cuff by a physician. With the subject seated for
at least 3 min, systolic blood pressure and ﬁfth-
phase diastolic blood pressure were measured
in each arm to the nearest 2 mm Hg. The
means of the right and left arm measurements
were used as each participant’s systolic and
diastolic blood pressures. 
Blood lead measurements. Blood samples
for lead measurement were taken in special
trace-metal-free tubes containing ethylenedi-
aminetetra-acetic acid, and sent to ESA
Laboratories, Inc. (Bedford, MA), for analy-
sis. After room temperature digestion with
nitric acid, the sample solution was cen-
trifuged and the supernatant was poured into
a sample cup. It was then analyzed by Zeeman
background-correlated flameless atomic
absorption (graphite furnace). The instru-
ment was calibrated after every 21 samples
with National Bureau of Standard Blood
Lead Standards materials (Gaithersburg,
MD). Ten percent of the samples were run in
duplicate; at least 10% of the analyses were
controls and 10% were blanks. A complete
calibration check was made after the last spec-
imen was analyzed. In tests on reference sam-
ples from the Centers for Disease Control and
Prevention (Atlanta, GA), the coefficient of
variation ranged from 8% for concentrations
< 10 to 30 μg/dL, to 1% for higher concen-
trations. In comparison to a National Bureau
of Standards (Gaithersburg, MD) target with
a known blood lead concentration of
5.7 μg/dL, 24 repeated measurements con-
ducted by ESA Labs using this method gave a
mean ± SD of 5.3 ± 1.23 μg/dL.
KXRF bone lead measurements. Bone lead
measurements were performed from each par-
ticipant’s mid-tibial shaft and patella with a
KXRF instrument (ABIOMED Inc, Danvers,
MA). The physical principles, technical speciﬁ-
cations, validation, and quality control proce-
dures of this (Burger et al. 1990; Hu et al.
1990, 1994) and other KXRF instruments
(Jones et al. 1987; Somervaille et al. 1985) are
described elsewhere. Because this instrument
provides a continuous unbiased point estimate
that oscillates around the true bone lead value,
negative point estimates are sometimes pro-
duced when the true bone lead value is close to
zero. An estimate of the uncertainty associated
with each instrument, derived from a good-
ness-of-ﬁt calculation of the spectrum curves
and equivalent to a single standard deviation, is
also provided. Although a minimum detectable
limit calculation of twice this value has been
proposed for interpreting an individual’s bone
lead estimate (Gordon et al. 1993), retention
of all point estimates makes better use of the
data in epidemiologic studies (Kim et al.
1995). As a standard quality-control procedure
of KXRF measurements, tibia and patella bone
lead measurements with uncertainty estimates
of > 10 μg/g and > 15 μg/g, respectively, of
bone mineral were excluded. For our study,
30-min measurements were taken at the mid-
shaft of the left tibia (representing cortical
bone) and at the left patella (representing tra-
becular bone), after each region was washed
with a 50% solution of isopropyl alcohol. The
KXRF beam collimator was sited perpendicular
to the bone surface for the tibia and 30 degrees
in the lateral direction for the patella.
Statistical analysis. We calculated univari-
ate statistics and examined them for cases and
noncases of IHD. We used chi-square or t-
tests to assess the difference across cases and
noncases. Blood and bone lead levels were
log-transformed because their distributions
were skewed. A value of 35 was added to tibia
and patella lead levels before log-transforma-
tion (Kim et al. 1995; Kosnett et al. 1994). 
We assessed the association between lead
levels and risk for subsequent development of
new IHD using Cox’s proportional hazards
models. The follow-up period started at the
time of baseline visit (after 1 September
1991) and lasted until the time of ﬁrst IHD
event or death from myocardial infarction,
whichever occurred ﬁrst. If the participant did
not have an IHD event, the follow-up period
ended on the date of last visit (before 31
December 2001) or 31 December 2001 (if
the participant had a visit after 31 December
2001). Because only the year of IHD event
was available, 31 December of the year in
which the event occurred was used to calcu-
late person-years for all incident cases. 
We selected possible confounders on the
basis of their biologic signiﬁcance and infor-
mation from previous studies. These covariates
included age, body mass index, education,
race, current smoking status, pack-years
smoked, alcohol intake (grams per day)
(Moller and Kristensen 1992; Pocock et al.
1988), history of diabetes mellitus and hyper-
tension (Barzilay et al. 1998; Castelli et al.
1989), family history of hypertension, dias-
tolic and systolic blood pressure, serum
triglycerides, serum high-density lipids, and
total serum cholesterol. Variables signiﬁcant at
the 0.10 level in univariate models were
included in ﬁnal multivariate models. Each of
the log-transformed lead biomarker variables
(blood lead, tibia lead, and patella lead) was
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models. We also analyzed blood lead as a cate-
gorical variable (≥ 5 μg/dL, ≥ 10 μg/dL, and
≥ 15 μg/dL) and bone lead in tertiles. To check
for any residual or negative confounding, all
covariates were again added, one at a time, in
the final regression models. We performed a
sensitivity analysis for all ﬁnal regression mod-
els after excluding patients with diabetes melli-
tus (Barzilay et al. 1998; Castelli et al. 1989). 
Statistical analysis was performed using
SAS for UNIX (version 9.0; SAS Institute
Inc., Cary, NC). The authors had full access
to the data and take responsibility for its
integrity. All authors have read and agree to
the manuscript as written.
Results
A comparison of participants included in our
study with nonparticipants in the KXRF bone
lead study, within the same time frame,
revealed no significant differences with
respect to age, race, body mass index, alcohol
intake, smoking, a family history of hyperten-
sion, systolic and diastolic blood pressure, and
a history of diabetes mellitus or hypertension
(data not shown). A similar comparison of
participants included in our study with those
who did not return for a follow-up visit dur-
ing our study time frame also yielded no sig-
niﬁcant differences between the two groups. 
Of the 837 participants in our study, an
IHD event occurred in 83 cases (70 nonfatal
and 13 fatal). The mean age of noncases (65.9
± 7.3 years) was similar to that of cases (67.5 ±
6.5 years). The distribution of other covari-
ates—including known risk factors for IHD
such as smoking, alcohol intake, systolic and
diastolic blood pressures, a history of diabetes
mellitus or hypertension, serum triglycerides,
and total serum cholesterol—was also similar
among cases and noncases (Table 1). However,
the person-time contributed by noncases was
significantly longer than cases, because cases
were censored once an IHD event occurred. 
The mean blood, tibia, and patella lead
levels were higher in IHD cases than in non-
cases. When blood lead level was examined as
a categorical variable, the proportion of cases
with a blood lead level ≥ 5 μg/dL was signiﬁ-
cantly higher than noncases. When bone lead
was examined in tertiles, a higher proportion
of cases were in the highest tertile of tibia and
patella lead level compared with noncases (for
tibia lead: 38.1% cases compared with 32.7%
noncases; for patella lead: 49.2% cases com-
pared with 30.8% noncases) (data not shown). 
Age and serum high-density lipids were
associated with IHD in multivariate Cox pro-
portional hazards regression models such that
the risk for IHD increased with increasing age
and decreased with increasing serum high-
density lipids (Table 2). When assessed as
continuous variables, an increase in blood or
bone lead level was associated with higher risk
for an IHD event. As a categorical variable,
blood lead level ≥ 5 μg/dL had a hazard ratio
of 1.73 [95% confidence interval (CI),
1.05–2.87] for IHD compared with blood
lead level < 5 μg/dL. A dose response was not
noted when tibia and patella lead levels were
analyzed in tertiles and quartiles.
The inclusion of other covariates known
to be risk factors for coronary disease—such
as body mass index, alcohol consumption,
current smoking, pack-years, a diagnosis of
diabetes, a diagnosis of hypertension, blood
pressure, family history of hypertension, total
serum cholesterol, and total serum trigly-
cerides—in the final regression models did
not alter our findings on the association
between lead and IHD (data not shown).
Our results were also similar when partici-
pants with diabetes were excluded from the
analysis (data not shown). 
The correlation between blood and bone
lead levels was modest (correlation coefﬁcient
= 0.30 for tibia and blood lead, and 0.37 for
patella and blood lead). As expected, tibia and
patella lead levels were strongly correlated
with each other (correlation coefficient =
0.78). When blood lead and one of the bone
lead variables were assessed in regression mod-
els simultaneously, the individual effect esti-
mates of blood and bone lead were only
moderately attenuated. The hazard ratio for
log blood lead was 1.24 (95% CI, 0.80–1.93)
and for log patella lead was 2.62 (95% CI,
0.99–6.93) when these variables were assessed
together in a multivariate model. Similarly,
the hazards ratio for blood lead was 1.38
(95% CI, 0.89–2.13) and that for tibia lead
was 1.55 (95% CI, 0.44–5.53) when these
variables were included together in the model.
Discussion
The relationship between biomarkers of long-
term lead exposure and IHD has not been pre-
viously assessed. In a longitudinal study of
837 middle-aged and elderly men followed
from 1 September 1991 through 31 December
2001, we found that the risk of future IHD
increases signiﬁcantly with increasing bone and
blood lead levels, after adjusting for potential
confounders. 
The relationship of lead exposure with
hypertension and increased blood pressure has
been established in previous studies (Cheng
et al. 2001; Harlan 1988; Hertz-Picciotto and
Croft 1993; Hu et al. 1996a; Kopp et al. 1988;
Lead and IHD
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Table 1. Baseline characteristics of IHD cases and noncases, Normative Aging Study, 1991–2001.
Noncases (n = 754) Cases (nonfatal n = 70; fatal n = 13)
Characteristic Totala No. (%) Range Totala No. (%) Range
Age (years)*
< 60 754 162 (21.5) — 83 10 (12.1) —
60–69 754 378 (50.1) — 83 48 (57.8) —
≥ 70 754 214 (28.4) — 83 25 (30.1) —
Race**
White 747 734 (98.3) — 82 78 (95.1) —
Black 747 13 (1.7) — 82 4 (4.9) —
Current smoker 754 60 (8.0) — 83 4 (4.8) —
Pack-years (among smokers)b 528 29.7 ± 23.7 0.10 to 145.5 61 34.0 ± 30.4 0.20 to 110.0
Body mass index (kg/meter2)b 749 28.0 ± 3.8 16.7 to 51.3 82 28.4 ± 3.8 19.6 to 41.5
Serum triglycerides (mg/dL)b 743 151.2 ± 93.9 24.0 to 978.0 83 146.5 ± 60.9 49.0 to 340.0
Total serum cholesterol (mg/dL)b 753 230.5 ± 38.7 130.0 to 438.0 83 232.7 ± 32.6 158.0 to 297.0
Serum high-density lipids (mg/dL)b* 730 49.4 ± 13.3 21 to 131 83 45.8 ± 10.3 21.0 to 85.0
Alcohol intake (gm/day)b 737 13.3 ± 17.5 0.0 to 104.1 80 11.2 ± 14.6 0.0 to 67.0
Systolic blood pressure (mm Hg)b 753 134.9 ± 17.0 91.0 to 215.0 83 136.4 ± 18.6 103.0 to 186.0
Diastolic blood pressure (mm Hg)b 753 82.0 ± 9.3 51.0 to 122.0 83 81.5 ± 11.3 56.0 to 110.0
Diabetes 754 81 (10.7) — 83 9 (10.8) —
Hypertension 754 341 (45.2) — 83 42 (50.6) —
Family history of hypertension 635 277 (43.6) — 72 30 (41.7) —
Person time (years)b* 754 6.9 ± 2.3 1.8 to 10.4 83 3.8 ± 2.7 0.08 to 10.7
Blood lead (µg/dL)b 738 6.2 ± 4.3 0.0 to 35.0 80 7.0 ± 3.8 1.0 to 20.0
Blood lead* tertiles
< 5 µg/dL 738 306 (41.5) — 64 22 (27.5) —
5–9.9 µg/dL 738 329 (44.6) — 64 43 (53.8) —
≥ 10 µg/dL 738 103 (14.0) — 64 15 (18.8) —
Patella lead (µg/g)b* 487 30.6 ± 19.7 –10.0 to 165.0 63 36.8 ± 20.8 5.0 to 101.0
Patella lead (µg/g)b* tertiles
Tertile 1 487 13.9 ± 4.9 –10.0 to 20.0 63 15.3 ± 4.3 5.0 to 19.0
Tertile 2 487 27.1 ± 4.1 21.0 to 34.0 63 25.7 ± 3.8 21.0 to 33.0
Tertile 3 487 52.5 ± 20.7 35.0 to 165.0 63 53.3 ± 17.3 35.0 to 101.0
Tibia lead (µg/g)b 486 21.4 ± 13.6 –3.0 to 126.0 63 24.2 ± 15.9 –5.0 to 75.0
Tibia lead (µg/g)b tertiles
Tertile 1 486 10.2 ± 3.8 –3.0 to 15.0 63 10.1 ± 5.3 –5.0 to 15.0
Tertile 2 486 19.1 ± 2.3 16.0 to 23.0 63 19.8 ± 2.2 16.0 to 23.0
Tertile 3 486 35.5 ± 14.4 24.0 to 126.0 63 39.5 ± 14.9 25.0 to 75.0
aTotal n for the respective variable. bMean ± SD. *p < 0.05 for cases versus noncases. **p < 0.10 for cases versus noncases.Martin et al. 2006; Moller and Kristensen
1992; Nash et al. 2003; Pirkle et al. 1985;
Schwartz 1991, 1995). Furthermore, it has also
been reported that higher blood lead levels lead
to increased mortality from cardiovascular
causes (Lustberg and Silbergeld 2002).
However, only three previous investigations
have assessed the association between blood
lead levels and heart disease (Kromhout 1988;
Moller and Kristensen 1992; Pocock et al.
1988). Pocock et al. (1988) followed 7,371
men 40–59 years of age in Britain for 6 years,
to assess the relationship between blood lead
levels at baseline and IHD. Although mean
blood lead concentration was significantly
higher in cases (0.786 μmole/L) than in non-
cases (0.735 μmole/L), there was no evidence
that blood lead was associated with IHD after
controlling for potential confounders. Moller
and Kristensen (1992) studied the risk of fatal
and nonfatal coronary heart disease and cardio-
vascular disease in 1,050 participants after
14 years of follow-up. Their results were simi-
lar to those of Pocock et al. in that blood lead
was associated with increased risk for coronary
heart disease (relative hazard = 2.14; p = 0.003)
and cardiovascular disease (relative hazard =
1.58; p = 0.05) in an unadjusted analysis; but
the association disappeared when confounders
were adjusted for. Another smaller study (n =
141) by Kromhout (1988) in the Netherlands
found no association between blood lead and
coronary heart disease in univariate and multi-
variate analysis. However, only 26 participants
had coronary heart disease in their 8 years of
follow-up data. A recent case report described a
patient with angina (severe spontaneous chest
pain with S-T elevation) who had a normal
coronary angiogram and blood lead level of
33 μg/dL (Oneglia et al. 1998). The patient
was chelated with EDTA, and described to be
normal during follow-up. The authors hypoth-
esized that lead exposure was possibly involved
in endothelial dysfunction and coronary spasm
in this case.
It is likely that previous studies (Kromhout
1988; Pocock et al. 1988), although suggestive
of a relationship between lead exposure and
heart disease, did not find an association in
multivariate analysis because of differences in
study population. Another likely reason is that
blood lead was used as a biomarker for expo-
sure. Lead accumulates in the skeleton, with a
half-life of years to decades (Manton 1985;
Rabinowitz et al. 1976). Bone is a repository for
90–95% of lead in adults (Barry and Mossman
1970; Saltzman et al. 1990; Schroeder and
Tipton 1968). Previous studies have shown that
bone lead levels remain elevated despite declines
in blood lead. Therefore, bone lead may be the
biomarker of choice for measurement of long-
term lead exposure. Bone lead levels have been
found to be better predictors than blood lead
when assessing outcomes such as hypertension
and cognitive declines in a number of recent
studies (Cheng et al. 2001; Hu et al. 1996a;
Schwartz et al. 2000; Weisskopf et al. 2004).
There is evidence that lead is released from
bone stores, especially during increased bone
turnover (Rabinowitz 1991; Silbergeld 1991).
This may contribute to increased blood lead in
persons with increased bone lead or increased
bone turnover. 
Blood and bone lead were associated
with increased risk for IHD in our study.
Furthermore, the effect estimates of blood
and bone lead were not attenuated when
assessed simultaneously, suggesting that both
contribute independently to IHD. It is
unclear why tibia lead was not significantly
associated with IHD, although the direction
of association was consistent with our overall
findings. The stronger association of patella
lead with IHD is noteworthy in that the
patella is composed of trabecular bone and is
known to have higher turnover rates and con-
tribute more to blood lead than the cortical
bone represented by tibia lead (Hu et al.
1996b). Because bone lead may contribute to
blood lead, particularly in our aging cohort,
which has had greater historic environmental
exposures and higher rates of bone resorption,
the association of blood lead with IHD is
plausible. It is also likely that persons in the
general population with high blood lead levels
have historically had higher levels of lead. In
summary, blood lead level reﬂects acute expo-
sure from circulating lead, whereas bone lead
reﬂects chronic exposure as well as the major
internal source of circulating blood lead. Both
factors likely play a role in predicting risk for
IHD. We suggest that future studies look at
both blood and bone lead when assessing the
risk for IHD from lead exposure.
The pathogenesis of the association
between lead exposure and IHD can be
explained by two mechanisms: One is media-
tion through increase in blood pressure, which
has been previously associated with an increase
in risk for ischemic and coronary heart disease
(Khot et al. 2003; MacMahon et al. 1990;
Tibblin et al. 1975; Wojtczak-Jaroszowa and
Kubow 1989); and the other is by atherogenic
process. Atherosclerosis can result from lead
exposure by inhibition of cytochrome P-450,
leading to accumulation of lipids in vessel
walls. Lead exposure can also lead to inhibition
of superoxide dismutase, an oxygen radical–
scavenging enzyme, leading to an increase in
serum lipid peroxide (Moller and Kristensen
1992; Wojtczak-Jaroszowa and Kubow 1989).
Serum peroxide is a risk factor for vascular
disease and thrombus formation.
Although lead levels have declined in the
United States and other industrialized
nations, low-level lead exposures still persist,
and exposure from higher lead levels in the
past is likely. Because the pathogenesis of
IHD is chronic and takes years to develop,
the public health implications of cumulative
lifetime lead exposure in the general popula-
tion are likely being currently realized and
will continue in the near future. 
Our study was limited by the unavailability
of exact date of onset for the IHD event.
Therefore, 31 December of the year of IHD
diagnosis was used in person-time calculations.
However, it is unlikely that this would lead to
a differential bias by IHD status. Because our
study population included only men and had
very few minority participants, our results may
not be generalized to races other than white or
to women. Our study also had a limited
number of IHD events. Therefore, residual
Jain et al.
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Table 2. Cox proportional hazards models for the association between biomarkers of lead level and IHD, Normative Aging Study, 1991–2001 [HR (95% CI)].
Model A Model B Model C Model D
Covariate Unadjusted (n = 787) (n = 787) (n = 532) (n = 531)
Age (years)
< 60 Reference Reference Reference Reference Reference
60–69 2.18 (1.10–4.32) 2.43 (1.19–4.97) 2.45 (1.20–5.03) 1.67 (0.77–3.64) 1.71 (0.78–3.76)
≥ 70 2.44 (1.16–5.10) 2.52 (1.15–5.49) 2.57 (1.18–5.61) 2.01 (0.83–4.84) 2.22 (0.91–5.42)
Black race 2.38 (0.87–6.49) 1.84 (0.58–5.90) 1.71 (0.53–5.53) 1.99 (0.61–6.45) 2.14 (0.66–6.94)
Serum high-density lipids (mg/dL) 0.97 (0.96–0.99) 0.97 (0.95–0.99) 0.97 (0.95–0.99) 0.98 (0.96–1.00) 0.98 (0.96–1.00)
Blood lead level ≥ 5 µg/dL 1.64 (1.00–2.68) 1.73 (1.05–2.87)* — — —
Blood lead level (µg/dL)a 1.40 (0.99–1.98) — 1.45 (1.01–2.06)* — —
Patella lead level (µg/g)a 3.27 (1.41–7.58) — — 2.64 (1.09–6.37)* —
Tibia lead level (µg/g)a 2.76 (0.94–8.12) — — — 1.84 (0.57–5.90)**
HR, hazard ratio; CI, conﬁdence interval. The hazard ratios and their statistical signiﬁcance for blood and bone lead were similar when other potential confounders such as smoking,
body mass index, alcohol consumption, blood pressure, family history of hypertension, and total serum cholesterol were included in the models.
aLogarithm of lead level. *p = 0.05;**p = 0.31.confounding unaccounted for in our analysis is
a possibility. This includes factors such as meas-
ures of socioeconomic status that are related to
lead levels. A lower socioeconomic status may
lead to inadequate health maintenance, thereby
increasing the risk for IHD. 
Conclusion
In summary, we found that men with
increased blood and bone lead levels were at an
increased risk for future IHD. Low-level lead
exposures in the recent past and higher past
exposures may contribute to the increased risk
for IHD. Although, the pathogenesis of IHD
is multifactorial, lead exposure may be one of
the risk factors for development of IHD. 
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